Sarepta Therapeutics, Inc. Forecast, price target & analysts
Sarepta Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Sarepta Therapeutics, Inc. Classifications & Recommendation:
Sarepta Therapeutics, Inc. Price Target
| Target Price | $45.90 |
| Price | $17.11 |
| Potential |
168.26%
register free of charge
|
| Number of Estimates | 27 |
|
27 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 .
The average Sarepta Therapeutics, Inc. target price is $45.90.
This is
168.26%
register free of charge
$194.25
1,035.30%
register free of charge
$10.10
40.97%
register free of charge
|
|
| A rating was issued by 32 analysts: 26 Analysts recommend Sarepta Therapeutics, Inc. to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of
168.26%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.90 | 2.41 |
| 52.97% | 26.87% | |
| EBITDA Margin | 11.59% | -3.72% |
| 154.13% | 132.09% | |
| Net Margin | 12.37% | -10.46% |
| 128.69% | 184.57% |
27 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2025. The average Sarepta Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sarepta Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.18 | -2.57 |
| 137.59% | 217.89% | |
| P/E | negative | |
| EV/Sales | 0.95 |
29 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sarepta Therapeutics, Inc....
Current Sarepta Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 25 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Jun 20 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Jun 20 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jun 18 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 25 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Jun 20 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Jun 20 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jun 18 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Jun 17 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
